Appointment of Joint Broker

19^th Sep 2016

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces the appointment of N+1 Singer as Joint Broker to the Company, alongside Panmure Gordon, with immediate effect. Panmure Gordon remains Nominated Adviser to the Company.

EKF Diagnostics Holdings plc Julian Baines, CEO Richard Evans, Finance Director and COO	00 44 29 2071 0570
Panmure Gordon (UK) Limited Peter Steel Paul Fincham	00 44 20 7886 2500
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF wins twice at the 2021 Small Cap Awards

EKF Diagnostics wins two awards at the Small Cap Awards in London.

EKF Diagnostics acquires ADL Health molecular diagnostic testing laboratory

New testing capacity complements EKF’s test kit manufacturing and point-of-care diagnostic instrument business

EKF Diagnostics to showcase at Medica 2021 STAT-Site® WB β-ketone and glucose handheld analyzer live & in person

EKF Diagnostics will be exhibiting live & in person at Medica (Hall 3 Stand B71) for the first time in mainland Europe in two years.

Medica 2021

Medica is the world’s largest medical trade fair. For more than 40 years it has been firmly established on every professional's calendar attracting over 40,000 delegates and over 5,000 exhibitors from 70 countries in 17 halls.

Luke Daum - inventor of PrimeStore® MTM - joins EKF Diagnostics as Chief Scientific Officer

Eminent infectious disease diagnostics expert to further boost EKF’s Life Science and Molecular Diagnostics offering